Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


APS arthritis guidelines

This article was originally published in The Tan Sheet

Executive Summary

Adults with osteoarthritis "should be encouraged to take 1,500 mg oral glucosamine sulfate daily," American Pain Society advises in recent "Guideline for the Management of Pain in Osteoarthritis, Rheumatoid Arthritis & Juvenile Chronic Arthritis." For chondroitin and SAM-e, APS concludes "until there have been longer-term studies and more standardization of recommendations can be made about their use." Acetaminophen remains "drug of choice" for mild to moderate arthritis pain, APS says, due to analgesic's mild side effects, OTC availability and low cost. However, guidelines note long-term use may be associated with chronic kidney failure, although effect is likely to be "very rare." Guidelines represent first evidence-based, multidisciplinary arthritis pain recommendations ever issued by APS...

You may also be interested in...

Coronavirus Update: BMS Expands Medicine Program, Cancer Research UK Cuts Funding

Bristol-Myers Squibb is to give away more medicines to uninsured US patients, Cancer Research UK tells of funding hardship, Oxford Biomedica joins a consortium to rapidly develop a vaccine, while a Korean company works on a stem cell therapy.

Inovio Confirms Frontrunner Status In COVID-19 Vaccine Race, But Can It Prove Skeptics Wrong?

Its ‘virus chasing’ habits has given Inovio a bad reputation. But with backing from Bill Gates, it has a chance to prove the doubters wrong

MDR Delay: Is It All Good News Or Does It Bring Its Own Problems?

In responding to industry’s plea for more time to comply with the EU’s MDR, will the European Commission’s proposed one-year delay also create some unwelcome repercussions that particularly impact manufacturers and notified bodies?





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts